PT-141 10mg

Compound Overview

PT-141 10mg is a lyophilized synthetic peptide preparation supplied by Amino Apex for qualified laboratory research. PT-141, also known as bremelanotide, is a cyclic heptapeptide derived from the melanocortin peptide family and structurally related to alpha-melanocyte-stimulating hormone (α-MSH). It has been investigated for its interaction with melanocortin receptors, particularly MC3R and MC4R, and its involvement in neuroendocrine signaling, receptor activation, and intracellular signal-transduction pathways. Published research has examined PT-141 in both experimental systems and controlled human studies, although those findings do not establish the identity, safety, or effectiveness of the Amino Apex research preparation.

Bremelanotide functions as a melanocortin receptor agonist and activates several members of the melanocortin receptor family. FDA pharmacology data report the order of receptor potency as MC1R > MC4R > MC3R > MC5R > MC2R, with MC1R and MC4R among the most pharmacologically relevant receptor interactions.

These properties make PT-141 relevant to laboratory investigations of central melanocortin signaling, GPCR pharmacology, peptide-receptor selectivity, neuroendocrine pathways, and melanocortin-associated neuronal signaling.

Published scientific literature has investigated PT-141 (bremelanotide) as a synthetic melanocortin receptor agonist. A 2019 peer-reviewed review published in Drugs examines bremelanotide's pharmacological characteristics, melanocortin receptor interactions, and clinical development. Earlier clinical research also investigated the pharmacodynamic activity of PT-141. A 2006 randomized, placebo-controlled study published in The Journal of Sexual Medicine evaluated physiological and subjective responses following administration of bremelanotide in a small group of participants. These publications provide scientific background and do not establish therapeutic effectiveness, safety, or pharmaceutical equivalence for the Amino Apex research material.

Molecular & Structural Research

PT-141 is a cyclic seven-amino-acid peptide represented as:

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Its structure contains:

Nle – Asp – His – D-Phe – Arg – Trp – Lys

where Nle represents norleucine and D-Phe represents D-phenylalanine.

The molecule contains an N-terminal acetyl group and an internal lactam cyclization between the Asp and Lys side chains, producing the characteristic cyclic peptide architecture. The FDA describes bremelanotide acetate using the same cyclic heptapeptide structure.

For the bremelanotide free-base form:

CAS Number: 189691-06-3
Molecular Formula: C₅₀H₆₈N₁₄O₁₀
Molecular Mass: approximately 1,025.2 g/mol.

The cyclic architecture and incorporation of non-natural residues make PT-141 relevant to peptide stability, conformational restriction, receptor-binding, and melanocortin structure-function research.

Research Applications

PT-141 may be studied in appropriately designed laboratory research involving:

• Melanocortin receptor pharmacology
• MC1R-associated signaling
• MC3R-associated signaling
• MC4R-associated signaling
• MC5R-associated signaling
• GPCR activation
• Central melanocortin pathways
• Hypothalamic signaling research
• Neuroendocrine signaling
• Peptide-receptor interaction studies
• Receptor selectivity research
• Cyclic peptide structure-function studies
• Melanocortin analogue characterization
• Peptide conformational research
• Comparative melanocortin research
• Analytical peptide characterization

MC3R and MC4R are particularly relevant to research on central melanocortin signaling, while melanocortin receptor biology more broadly includes five related GPCR subtypes with distinct tissue distributions and signaling roles.

These categories describe areas of scientific investigation and do not constitute therapeutic or clinical-use recommendations.

Preclinical Research Context

Bremelanotide has been investigated across receptor-expression systems, animal models, pharmacological studies, and human clinical research.

Experimental studies have examined its interaction with central melanocortin receptors, particularly receptor systems expressed within the central nervous system. Research has also investigated the relationship between melanocortin receptor activation and neurotransmitter-associated signaling, hypothalamic pathways, and neuroendocrine regulation.

Although bremelanotide has an established clinical-development history, the exact pathway linking melanocortin receptor activation to some observed physiological responses remains incompletely defined. FDA labeling specifically notes that the mechanism connecting receptor activation to its approved clinical effect is not fully established.

Experimental findings should therefore be interpreted within the specific receptor system, biological model, assay conditions, and limitations of each study.

Analytical Documentation

Amino Apex provides batch-specific analytical documentation for tested lots. Individual lot documentation may include chromatographic purity analysis and other analytical information associated with the tested sample.

Because analytical characteristics may differ by production lot, the Certificate of Analysis for the applicable batch should be used as the source of measured purity and quality-control results.

Refer to the COA panel on this page or the Amino Apex COA Library for available batch documentation.

Storage & Laboratory Handling

This material should be handled only by qualified personnel using procedures appropriate for laboratory peptide materials.

Storage and handling should follow the conditions specified in the applicable product and batch documentation.

Experimental preparation, concentration, assay conditions, and analytical methodology should be established by qualified researchers according to the requirements of their specific laboratory system.

Research Use Only

For laboratory research use only.

This material is not intended for human or animal use. It is not intended for diagnostic, therapeutic, food, cosmetic, or household applications and is not intended to diagnose, treat, cure, prevent, or mitigate any disease or medical condition.